(NASDAQ: ADAG) Adagene's forecast annual revenue growth rate of 386.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.2%.
Adagene's revenue in 2026 is $103,204.On average, 6 Wall Street analysts forecast ADAG's revenue for 2026 to be $360,554,212, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,113,476,244. On average, 6 Wall Street analysts forecast ADAG's revenue for 2027 to be $406,978,513, with the lowest ADAG revenue forecast at $0, and the highest ADAG revenue forecast at $1,113,476,244.
In 2028, ADAG is forecast to generate $751,154,609 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,092,989,568.